Skip to main content

NUEVAS ESTRATEGIAS DE INHIBICION DE LA VIA HEDGEHOG COMO DIANAS TERAPEUTICAS EN EL RABDOMIOSARCOMA.

PI18/00398

•
Funding agency name Instituto de Salud Carlos III
Funding agency acronym ISCIII
Program Programa Estatal de Fomento de la Investigación Científica y Técnica de Excelencia
Subprogram Subprograma Estatal de Generación de Conocimiento
Call Proyectos de Investigación en Salud
Call year 2018
State Plan 2013-2016 Plan Estatal de Investigación Científica y Técnica y de Innovación
Beneficiary centre FUNDACION INSTITUTO DE INVESTIGACION VALLE DE HEBRON
Execution centre INSTITUTO DE INVESTIGACION HOSPITAL UNIVERSITARIO VALLE DE HEBRON (VHIR)

Resultados relacionados

Resultados totales (Incluyendo duplicados): 10
Encontrada(s) 1 página(s)

Recercat. Dipósit de la Recerca de Catalunya
Publication Artículo científico (JournalArticle)

Dickkopf-1 Inhibition Reactivates Wnt/β-Catenin Signaling in Rhabdomyosarcoma, Induces Myogenic Markers In Vitro and Impairs Tumor Cell Survival In Vivo

  • Giralt Buch, Irina
  • Gallo, Gabriel Osvaldo
  • Zarzosa Martinez, Patricia
  • Pons Barcons, Guillem
  • Magdaleno Cazon, Ainara
  • Segura Ginard, Miguel
  • Sábado Álvarez, Constantino
  • Hladun Alvaro, Raquel
  • Sánchez de Toledo Codina, Josep
  • Moreno Martín-Retortillo, Lucas
  • Gallego Melcón, Soledad
  • Roma Castanyer, Josep
  • Navarro Barea, Natalia
Dickkopf proteins; Differentiation, Proteínas Dickkopf; Diferenciación, Proteïnes Dickkopf; Diferenciació, The Wnt/β-catenin signaling pathway plays a pivotal role during embryogenesis and its deregulation is a key mechanism in the origin and progression of several tumors. Wnt antagonists have been described as key modulators of Wnt/β-catenin signaling in cancer, with Dickkopf-1 (DKK-1) being the most studied member of the DKK family. Although the therapeutic potential of DKK-1 inhibition has been evaluated in several diseases and malignancies, little is known in pediatric tumors. Only a few works have studied the genetic inhibition and function of DKK-1 in rhabdomyosarcoma. Here, for the first time, we report the analysis of the therapeutic potential of DKK-1 pharmaceutical inhibition in rhabdomyosarcoma, the most common soft tissue sarcoma in children. We performed DKK-1 inhibition via shRNA technology and via the chemical inhibitor WAY-2626211. Its inhibition led to β-catenin activation and the modulation of focal adhesion kinase (FAK), with positive effects on in vitro expression of myogenic markers and a reduction in proliferation and invasion. In addition, WAY-262611 was able to impair survival of tumor cells in vivo. Therefore, DKK-1 could constitute a molecular target,, This research was supported by grants from the following: Institut Català d’Oncologia (ICO); Instituto de Salud Carlos III (PI18/00398); Fundació A. BOSCH; Rotary Clubs Barcelona Eixample, Barcelona Diagonal, Santa Coloma de Gramanet, München-Blutenburg, Deutschland Gemeindienst e.V. and others from Barcelona and province; FERO Foundation; Eric Abidal Foundation; “del Hospital a la catedral” Initiative by Xavi Vallès; and “Mi compañero de viaje”.
Recercat. Dipósit de la Recerca de Catalunya
Publication Artículo científico (JournalArticle)

Dickkopf Proteins and Their Role in Cancer: A Family of Wnt Antagonists with a Dual Role

  • Giralt Buch, Irina
  • Gallo, Gabriel Osvaldo
  • Zarzosa Martinez, Patricia
  • Pons Barcons, Guillem
  • Magdaleno Cazon, Ainara
  • Segura Ginard, Miguel
  • Sánchez de Toledo Codina, Josep
  • Moreno Martín-Retortillo, Lucas
  • Gallego Melcón, Soledad
  • Roma Castanyer, Josep
  • Navarro Barea, Natalia
Dickkopf; Wnt antagonists; Wnt signaling, Dickkopf; Antagonistes Wnt; Senyalització Wnt, Dickkopf; Antagonistas Wnt; Señalización Wnt, The Wnt signaling pathway regulates crucial aspects such as cell fate determination, cell polarity and organogenesis during embryonic development. Wnt pathway deregulation is a hallmark of several cancers such as lung, gastric and liver cancer, and has been reported to be altered in others. Despite the general agreement reached by the scientific community on the oncogenic potential of the central components of the pathway, the role of the antagonist proteins remains less clear. Deregulation of the pathway may be caused by overexpression or downregulation of a wide range of antagonist proteins. Although there is growing information related to function and regulation of Dickkopf (DKK) proteins, their pharmacological potential as cancer therapeutics still has not been fully developed. This review provides an update on the role of DKK proteins in cancer and possible potential as therapeutic targets for the treatment of cancer; available compounds in pre-clinical or clinical trials are also reviewed., This work was supported by grants from Institut Català d’Oncologia (ICO); Instituto de Salud Carlos III (PI18/00398 and PI21/00640); La Marató de TV3 (201937); Fundació A.BOSCH; Rotary Clubs Barcelona Eixample, Barcelona Diagonal, Santa Coloma de Gramanet, München-Blutenburg, Deutschland Gemeindienst e.V. and others from Barcelona and province; Eric Abidal Foundation and Mi compañero de viaje.
Recercat. Dipósit de la Recerca de Catalunya
Publication Artículo científico (JournalArticle)

Targeting the Hedgehog Pathway in Rhabdomyosarcoma

  • Zarzosa Martinez, Patricia
  • Hladun Alvaro, Raquel
  • Gallo, Gabriel Osvaldo
  • Pons Barcons, Guillem
  • Segura Ginard, Miguel
  • Sánchez de Toledo Codina, Josep
  • Moreno Martín-Retortillo, Lucas
  • Gallego Melcón, Soledad
  • Roma Castanyer, Josep
  • Sansa Girona, Júlia
  • Garcia Gilabert, Lia
  • Guillén Burrieza, Gabriela
Embryonic pathways; Paediatric cancer; Soft tissue sarcomas, Vies embrionàries; Càncer pediàtric; Sarcomes de teixits tous, Vías embrionarias; Cáncer pediátrico; Sarcomas de tejidos blandos, Aberrant activation of the Hedgehog (Hh) signalling pathway is known to play an oncogenic role in a wide range of cancers; in the particular case of rhabdomyosarcoma, this pathway has been demonstrated to be an important player for both oncogenesis and cancer progression. In this review, after a brief description of the pathway and the characteristics of its molecular components, we describe, in detail, the main activation mechanisms that have been found in cancer, including ligand-dependent, ligand-independent and non-canonical activation. In this context, the most studied inhibitors, i.e., SMO inhibitors, have shown encouraging results for the treatment of basal cell carcinoma and medulloblastoma, both tumour types often associated with mutations that lead to the activation of the pathway. Conversely, SMO inhibitors have not fulfilled expectations in tumours—among them sarcomas—mostly associated with ligand-dependent Hh pathway activation. Despite the controversy existing regarding the results obtained with SMO inhibitors in these types of tumours, several compounds have been (or are currently being) evaluated in sarcoma patients. Finally, we discuss some of the reasons that could explain why, in some cases, encouraging preclinical data turned into disappointing results in the clinical setting., This article was funded by grants from: Institut Català d’Oncologia (ICO); Instituto de Salud Carlos III (PI18/00398 and FI18/00178); ACCIÓ (COMRDI15-1-0014); Fundació la Marató de TV3; Fundació Albert Bosch; Rotary Clubs Barcelona Eixample, Barcelona Diagonal, Santa Coloma de Gramanet, München-Blutenburg, Deutschland Gemeindienst e.V. and others from Barcelona and province; Fundation Amics Joan Petit; Del Hospital a la cathedral Initiative by Xavi Vallès; and Mi compañero de viaje Association.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Targeting the Hedgehog Pathway in Rhabdomyosarcoma

  • Zarzosa, Patricia|||0000-0002-9711-8384
  • García-Gilabert, Lia|||0000-0003-2079-7232
  • Hladun, Raquel|||0000-0002-3191-1750
  • Guillén, Gabriela|||0000-0001-5632-2672
  • Gallo Oller, Gabriel|||0000-0002-3864-1941
  • Pons, Guillem|||0000-0001-8128-740X
  • Sansa-Girona, Julia
  • Segura, Miguel F.|||0000-0003-0916-3618
  • Sánchez de Toledo Codina, José|||0000-0002-1034-1920
  • Moreno Martin Retortillo, Lucas|||0000-0002-0708-1670
  • Gallego, Soledad|||0000-0002-4712-9624
  • Roma, Josep|||0000-0001-7692-6123
In the first sections of this review, we provide a comprehensive description of the Hedgehog signalling pathway in mammals and the main general models of pathway activation. Subsequently, the review focuses on the oncogenic role played by this pathway in rhabdomyosarcoma and the inhibitors developed to date, as well as the clinical trials available in sarcomas. Finally, we provide a discussion and critical review of the results obtained in the clinical setting and their strong dependency on the type of tumour. In some cases, strong discrepancies between encouraging preclinical data and clinical trial results are clearly evident. Aberrant activation of the Hedgehog (Hh) signalling pathway is known to play an oncogenic role in a wide range of cancers; in the particular case of rhabdomyosarcoma, this pathway has been demonstrated to be an important player for both oncogenesis and cancer progression. In this review, after a brief description of the pathway and the characteristics of its molecular components, we describe, in detail, the main activation mechanisms that have been found in cancer, including ligand-dependent, ligand-independent and non-canonical activation. In this context, the most studied inhibitors, i.e., SMO inhibitors, have shown encouraging results for the treatment of basal cell carcinoma and medulloblastoma, both tumour types often associated with mutations that lead to the activation of the pathway. Conversely, SMO inhibitors have not fulfilled expectations in tumours-among them sarcomas-mostly associated with ligand-dependent Hh pathway activation. Despite the controversy existing regarding the results obtained with SMO inhibitors in these types of tumours, several compounds have been (or are currently being) evaluated in sarcoma patients. Finally, we discuss some of the reasons that could explain why, in some cases, encouraging preclinical data turned into disappointing results in the clinical setting.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Dickkopf Proteins and Their Role in Cancer, A Family of Wnt Antagonists with a Dual Role

  • Giralt, Irina|||0000-0002-9094-4325
  • Gallo Oller, Gabriel|||0000-0002-3864-1941
  • Navarro Barea, Natalia|||0000-0002-2160-6656
  • Zarzosa, Patricia|||0000-0002-9711-8384
  • Pons, Guillem|||0000-0001-8128-740X
  • Magdaleno, Ainara|||0000-0002-2718-3244
  • Segura, Miguel F.|||0000-0003-0916-3618
  • Sánchez de Toledo, Joan|||0000-0002-9108-4750
  • Moreno Martin Retortillo, Lucas|||0000-0002-0708-1670
  • Gallego, Soledad|||0000-0002-4712-9624
  • Roma, Josep|||0000-0001-7692-6123
The Wnt signaling pathway regulates crucial aspects such as cell fate determination, cell polarity and organogenesis during embryonic development. Wnt pathway deregulation is a hallmark of several cancers such as lung, gastric and liver cancer, and has been reported to be altered in others. Despite the general agreement reached by the scientific community on the oncogenic potential of the central components of the pathway, the role of the antagonist proteins remains less clear. Deregulation of the pathway may be caused by overexpression or downregulation of a wide range of antagonist proteins. Although there is growing information related to function and regulation of Dickkopf (DKK) proteins, their pharmacological potential as cancer therapeutics still has not been fully developed. This review provides an update on the role of DKK proteins in cancer and possible potential as therapeutic targets for the treatment of cancer; available compounds in pre-clinical or clinical trials are also reviewed.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Integrin alpha9 emerges as a key therapeutic target to reduce metastasis in rhabdomyosarcoma and neuroblastoma

  • Navarro Barea, Natalia|||0000-0002-2160-6656
  • Molist, Carla|||0000-0003-3251-0083
  • Sansa-Girona, Júlia|||0000-0003-3285-7845
  • Zarzosa, Patricia|||0000-0002-9711-8384
  • Gallo Oller, Gabriel|||0000-0002-3864-1941
  • Pons, Guillem|||0000-0001-8128-740X
  • Magdaleno, Ainara|||0000-0002-2718-3244
  • Guillén, Gabriela|||0000-0001-5632-2672
  • Hladun, Raquel|||0000-0002-3191-1750
  • Garrido, Marta
  • Segura, Miguel F.|||0000-0003-0916-3618
  • Hontecillas-Prieto, L.
  • De Álava, Enrique|||0000-0001-8400-046X
  • Ponsati, B.
  • Fernández-Carneado, J.
  • Almazán-Moga, Anna
  • Vallès-Miret, M.
  • Farrera-Sinfreu, J.
  • Sánchez de Toledo Codina, José|||0000-0002-1034-1920
  • Moreno Martin Retortillo, Lucas|||0000-0002-0708-1670
  • Gallego, Soledad|||0000-0002-4712-9624
  • Roma, Josep|||0000-0001-7692-6123
The majority of current cancer therapies are aimed at reducing tumour growth, but there is lack of viable pharmacological options to reduce the formation of metastasis. This is a paradox, since more than 90% of cancer deaths are attributable to metastatic progression. Integrin alpha9 (ITGA9) has been previously described as playing an essential role in metastasis; however, little is known about the mechanism that links this protein to this process, being one of the less studied integrins. We have now deciphered the importance of ITGA9 in metastasis and provide evidence demonstrating its essentiality for metastatic dissemination in rhabdomyosarcoma and neuroblastoma. However, the most translational advance of this study is to reveal, for the first time, the possibility of reducing metastasis by pharmacological inhibition of ITGA9 with a synthetic peptide simulating a key interaction domain of ADAM proteins, in experimental metastasis models, not only in childhood cancers but also in a breast cancer model.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Dickkopf-1 Inhibition Reactivates Wnt/β-Catenin Signaling in Rhabdomyosarcoma, Induces Myogenic Markers In Vitro and Impairs Tumor Cell Survival In Vivo

  • Giralt, Irina|||0000-0002-9094-4325
  • Gallo Oller, Gabriel|||0000-0002-3864-1941
  • Navarro Barea, Natalia|||0000-0002-2160-6656
  • Zarzosa, Patricia|||0000-0002-9711-8384
  • Pons, Guillem|||0000-0001-8128-740X
  • Magdaleno, Ainara|||0000-0002-2718-3244
  • Segura, Miguel F.|||0000-0003-0916-3618
  • Sábado, Constantino|||0000-0003-3956-5466
  • Hladun, Raquel|||0000-0002-3191-1750
  • Arango, Diego|||0000-0003-2953-3284
  • Sánchez de Toledo Codina, José|||0000-0002-1034-1920
  • Moreno Martin Retortillo, Lucas|||0000-0002-0708-1670
  • Gallego, Soledad|||0000-0002-4712-9624
  • Roma, Josep|||0000-0001-7692-6123
The Wnt/β-catenin signaling pathway plays a pivotal role during embryogenesis and its deregulation is a key mechanism in the origin and progression of several tumors. Wnt antagonists have been described as key modulators of Wnt/β-catenin signaling in cancer, with Dickkopf-1 (DKK-1) being the most studied member of the DKK family. Although the therapeutic potential of DKK-1 inhibition has been evaluated in several diseases and malignancies, little is known in pediatric tumors. Only a few works have studied the genetic inhibition and function of DKK-1 in rhabdomyosarcoma. Here, for the first time, we report the analysis of the therapeutic potential of DKK-1 pharmaceutical inhibition in rhabdomyosarcoma, the most common soft tissue sarcoma in children. We performed DKK-1 inhibition via shRNA technology and via the chemical inhibitor WAY-2626211. Its inhibition led to β-catenin activation and the modulation of focal adhesion kinase (FAK), with positive effects on in vitro expression of myogenic markers and a reduction in proliferation and invasion. In addition, WAY-262611 was able to impair survival of tumor cells in vivo. Therefore, DKK-1 could constitute a molecular target, which could lead to novel therapeutic strategies in RMS, especially in those patients with high DKK-1 expression.
Scientia. Dipòsit d'Informació Digital del Departament de Salut
Publication Artículo científico (JournalArticle)

Dickkopf Proteins and Their Role in Cancer: A Family of Wnt Antagonists with a Dual Role

  • Giralt Buch, Irina
  • Gallo, Gabriel Osvaldo
  • Zarzosa Martinez, Patricia
  • Pons Barcons, Guillem
  • Magdaleno Cazon, Ainara
  • Segura Ginard, Miguel
  • Sánchez de Toledo Codina, Josep
  • Moreno Martín-Retortillo, Lucas
  • Gallego Melcón, Soledad
  • Roma Castanyer, Josep
  • Navarro Barea, Natalia
Dickkopf; Wnt antagonists; Wnt signaling, Dickkopf; Antagonistes Wnt; Senyalització Wnt, Dickkopf; Antagonistas Wnt; Señalización Wnt, The Wnt signaling pathway regulates crucial aspects such as cell fate determination, cell polarity and organogenesis during embryonic development. Wnt pathway deregulation is a hallmark of several cancers such as lung, gastric and liver cancer, and has been reported to be altered in others. Despite the general agreement reached by the scientific community on the oncogenic potential of the central components of the pathway, the role of the antagonist proteins remains less clear. Deregulation of the pathway may be caused by overexpression or downregulation of a wide range of antagonist proteins. Although there is growing information related to function and regulation of Dickkopf (DKK) proteins, their pharmacological potential as cancer therapeutics still has not been fully developed. This review provides an update on the role of DKK proteins in cancer and possible potential as therapeutic targets for the treatment of cancer; available compounds in pre-clinical or clinical trials are also reviewed., This work was supported by grants from Institut Català d’Oncologia (ICO); Instituto de Salud Carlos III (PI18/00398 and PI21/00640); La Marató de TV3 (201937); Fundació A.BOSCH; Rotary Clubs Barcelona Eixample, Barcelona Diagonal, Santa Coloma de Gramanet, München-Blutenburg, Deutschland Gemeindienst e.V. and others from Barcelona and province; Eric Abidal Foundation and Mi compañero de viaje.
Scientia. Dipòsit d'Informació Digital del Departament de Salut
Publication Artículo científico (JournalArticle)

Dickkopf-1 Inhibition Reactivates Wnt/β-Catenin Signaling in Rhabdomyosarcoma, Induces Myogenic Markers In Vitro and Impairs Tumor Cell Survival In Vivo

  • Giralt Buch, Irina
  • Gallo, Gabriel Osvaldo
  • Zarzosa Martinez, Patricia
  • Pons Barcons, Guillem
  • Magdaleno Cazon, Ainara
  • Segura Ginard, Miguel
  • Sábado Álvarez, Constantino
  • Hladun Alvaro, Raquel
  • Sánchez de Toledo Codina, Josep
  • Moreno Martín-Retortillo, Lucas
  • Gallego Melcón, Soledad
  • Roma Castanyer, Josep
  • Navarro Barea, Natalia
Dickkopf proteins; Differentiation, Proteínas Dickkopf; Diferenciación, Proteïnes Dickkopf; Diferenciació, The Wnt/β-catenin signaling pathway plays a pivotal role during embryogenesis and its deregulation is a key mechanism in the origin and progression of several tumors. Wnt antagonists have been described as key modulators of Wnt/β-catenin signaling in cancer, with Dickkopf-1 (DKK-1) being the most studied member of the DKK family. Although the therapeutic potential of DKK-1 inhibition has been evaluated in several diseases and malignancies, little is known in pediatric tumors. Only a few works have studied the genetic inhibition and function of DKK-1 in rhabdomyosarcoma. Here, for the first time, we report the analysis of the therapeutic potential of DKK-1 pharmaceutical inhibition in rhabdomyosarcoma, the most common soft tissue sarcoma in children. We performed DKK-1 inhibition via shRNA technology and via the chemical inhibitor WAY-2626211. Its inhibition led to β-catenin activation and the modulation of focal adhesion kinase (FAK), with positive effects on in vitro expression of myogenic markers and a reduction in proliferation and invasion. In addition, WAY-262611 was able to impair survival of tumor cells in vivo. Therefore, DKK-1 could constitute a molecular target,, This research was supported by grants from the following: Institut Català d’Oncologia (ICO); Instituto de Salud Carlos III (PI18/00398); Fundació A. BOSCH; Rotary Clubs Barcelona Eixample, Barcelona Diagonal, Santa Coloma de Gramanet, München-Blutenburg, Deutschland Gemeindienst e.V. and others from Barcelona and province; FERO Foundation; Eric Abidal Foundation; “del Hospital a la catedral” Initiative by Xavi Vallès; and “Mi compañero de viaje”.
Scientia. Dipòsit d'Informació Digital del Departament de Salut
Publication Artículo científico (JournalArticle)

Targeting the Hedgehog Pathway in Rhabdomyosarcoma

  • Zarzosa Martinez, Patricia
  • Hladun Alvaro, Raquel
  • Gallo, Gabriel Osvaldo
  • Pons Barcons, Guillem
  • Segura Ginard, Miguel
  • Sánchez de Toledo Codina, Josep
  • Moreno Martín-Retortillo, Lucas
  • Gallego Melcón, Soledad
  • Roma Castanyer, Josep
  • Sansa Girona, Júlia
  • Garcia Gilabert, Lia
  • Guillén Burrieza, Gabriela
Embryonic pathways; Paediatric cancer; Soft tissue sarcomas, Vies embrionàries; Càncer pediàtric; Sarcomes de teixits tous, Vías embrionarias; Cáncer pediátrico; Sarcomas de tejidos blandos, Aberrant activation of the Hedgehog (Hh) signalling pathway is known to play an oncogenic role in a wide range of cancers; in the particular case of rhabdomyosarcoma, this pathway has been demonstrated to be an important player for both oncogenesis and cancer progression. In this review, after a brief description of the pathway and the characteristics of its molecular components, we describe, in detail, the main activation mechanisms that have been found in cancer, including ligand-dependent, ligand-independent and non-canonical activation. In this context, the most studied inhibitors, i.e., SMO inhibitors, have shown encouraging results for the treatment of basal cell carcinoma and medulloblastoma, both tumour types often associated with mutations that lead to the activation of the pathway. Conversely, SMO inhibitors have not fulfilled expectations in tumours—among them sarcomas—mostly associated with ligand-dependent Hh pathway activation. Despite the controversy existing regarding the results obtained with SMO inhibitors in these types of tumours, several compounds have been (or are currently being) evaluated in sarcoma patients. Finally, we discuss some of the reasons that could explain why, in some cases, encouraging preclinical data turned into disappointing results in the clinical setting., This article was funded by grants from: Institut Català d’Oncologia (ICO); Instituto de Salud Carlos III (PI18/00398 and FI18/00178); ACCIÓ (COMRDI15-1-0014); Fundació la Marató de TV3; Fundació Albert Bosch; Rotary Clubs Barcelona Eixample, Barcelona Diagonal, Santa Coloma de Gramanet, München-Blutenburg, Deutschland Gemeindienst e.V. and others from Barcelona and province; Fundation Amics Joan Petit; Del Hospital a la cathedral Initiative by Xavi Vallès; and Mi compañero de viaje Association.